Evaluating the Home-based Intervention Strategy (HIS-UK) to reduce new Chlamydia infection among young men aged 16-25 years by promoting correct and consistent condom use: What is the cost effectiveness of two different delivery models (face-to-face and digital delivery)?

Evaluation of HIS-UK

- This protocol has regard for the HRA guidance and order of content
RESEARCH REFERENCE NUMBERS
Funder: NIHR Public Health Research Programme
PHR project ref: 17/54/06

TRIAL REGISTRY NUMBER AND DATE
ISRCTN registration: 11400820
Date: 23/10/2019

PROTOCOL VERSION NUMBER AND DATE
Version: 4
Date: 03 April 2020

OTHER RESEARCH REFERENCE NUMBERS
REC ref: 19/SC/0486

SPONSOR / CO-SPONSORS / JOINT-SPONSORS
Chief investigator: Professor Cynthia Graham
Sponsor: University of Southampton (UK)
SIGNATURE PAGE

The undersigned confirm that the following protocol has been agreed and accepted and that the Chief Investigator agrees to conduct the trial in compliance with the approved protocol and will adhere to the principles outlined in the Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031), amended regulations (SI 2006/1928) and any subsequent amendments of the clinical trial regulations, GCP guidelines, the Sponsor’s (and any other relevant) SOPs, and other regulatory requirements as amended.

I agree to ensure that the confidential information contained in this document will not be used for any other purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of the Sponsor.

I also confirm that I will make the findings of the trial publically available through publication or other dissemination tools without any unnecessary delay and that an honest accurate and transparent account of the trial will be given; and that any discrepancies and serious breaches of GCP from the trial as planned in this protocol will be explained.

Chief Investigator:
Signature: 
..............................................................................................
Date: 
......../....../......

Name: (please print):
..............................................................................................

Study Statistician:
Signature: 
..............................................................................................
Date: 
......../....../......

Name:
..............................................................................................
# KEY TRIAL CONTACTS

<table>
<thead>
<tr>
<th>Role</th>
<th>Contact Details</th>
</tr>
</thead>
</table>
| **Chief Investigator**      | Prof. Cynthia Graham  
c.a.graham@soton.ac.uk  
02380 59 30 91 |
| **Research Co-ordinator**   | Dr. Nicole Stone  
ncs@soton.ac.uk  
02380 59 77 70 |
| **Study Statistician**      | Prof. Stephen Bremner  
s.bremner@bsms.ac.uk |
| **Clinical Trials Unit Operational Manager** | Nicky Perry  
n.perry@bsms.ac.uk  
01273 64 14 69 |
| **Clinical Trials Unit Trial Manager** | Ye To  
Y.To@bsms.ac.uk  
01273 64 14 37 |
| **Sponsor**                 | University of Southampton |
| **Funder(s)**               | NIHR Public Health Research Programme  
Research Manager – Dr Shelia Turner  
Shelia.Turner@nihr.ac.uk  
02380 59 57 57 |
i. LIST of CONTENTS

<table>
<thead>
<tr>
<th>GENERAL INFORMATION</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>TITLE PAGE</td>
<td>1</td>
</tr>
<tr>
<td>RESEARCH REFERENCE NUMBERS</td>
<td>2</td>
</tr>
<tr>
<td>SIGNATURE PAGE</td>
<td>3</td>
</tr>
<tr>
<td>KEY TRIAL CONTACTS</td>
<td>4</td>
</tr>
<tr>
<td>i. LIST of CONTENTS</td>
<td>5</td>
</tr>
<tr>
<td>ii. LIST OF ABBREVIATIONS</td>
<td>6</td>
</tr>
<tr>
<td>iii. TRIAL SUMMARY</td>
<td>7</td>
</tr>
<tr>
<td>iv. FUNDING</td>
<td>8</td>
</tr>
<tr>
<td>v. ROLE OF SPONSOR AND FUNDER</td>
<td>8</td>
</tr>
<tr>
<td>vi. ROLES &amp; RESPONSIBILITIES OF TRIAL MANAGEMENT COMMITTEES,</td>
<td>8</td>
</tr>
<tr>
<td>GROUPS AND INDIVIDUALS</td>
<td></td>
</tr>
<tr>
<td>vii. KEYWORDS</td>
<td>8</td>
</tr>
<tr>
<td>viii. TRIAL FLOW CHART</td>
<td>9</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SECTION</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. BACKGROUND AND RATIONALE</td>
<td>10-11</td>
</tr>
<tr>
<td>2. ASSESSMENT AND MANAGEMENT OF RISK</td>
<td>11-12</td>
</tr>
<tr>
<td>3. OBJECTIVES AND OUTCOME MEASURES/ENDPOINTS</td>
<td>12-13</td>
</tr>
<tr>
<td>4. TRIAL DESIGN</td>
<td>14</td>
</tr>
<tr>
<td>5. TRIAL SETTING</td>
<td>14</td>
</tr>
<tr>
<td>6. PARTICIPANT ELIGIBILITY CRITERIA</td>
<td>14</td>
</tr>
<tr>
<td>7. TRIAL PROCEDURES AND TREATMENTS</td>
<td>15-25</td>
</tr>
<tr>
<td>8. SAFETY</td>
<td>26-30</td>
</tr>
<tr>
<td>9. STATISTICS AND DATA ANALYSIS</td>
<td>30-33</td>
</tr>
<tr>
<td>10. DATA MANAGEMENT</td>
<td>34-36</td>
</tr>
<tr>
<td>11. MONITORING, AUDIT &amp; INSPECTION</td>
<td>36</td>
</tr>
<tr>
<td>12. ETHICAL AND REGULATORY CONSIDERATIONS</td>
<td>36-39</td>
</tr>
<tr>
<td>13. DISSEMINATION POLICY</td>
<td>39</td>
</tr>
<tr>
<td>14. REFERENCES</td>
<td>40-42</td>
</tr>
<tr>
<td>15. VERSION HISTORY</td>
<td>43</td>
</tr>
</tbody>
</table>
## ii. LIST OF ABBREVIATIONS

Define all unusual or 'technical' terms related to the trial. Add or delete as appropriate to your trial. Maintain alphabetical order for ease of reference.

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>AR</td>
<td>Adverse Reaction</td>
</tr>
<tr>
<td>BSCTU</td>
<td>Brighton and Sussex Clinical Trials Unit</td>
</tr>
<tr>
<td>CI</td>
<td>Chief Investigator</td>
</tr>
<tr>
<td>CRF</td>
<td>Case Report Form</td>
</tr>
<tr>
<td>CTU</td>
<td>Clinical Trials Unit</td>
</tr>
<tr>
<td>DMC</td>
<td>Data Monitoring Committee</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>ICF</td>
<td>Informed Consent Form</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use.</td>
</tr>
<tr>
<td>ISF</td>
<td>Investigator Site File (This forms part of the TMF)</td>
</tr>
<tr>
<td>ISRCTN</td>
<td>International Standard Randomised Controlled Trials Number</td>
</tr>
<tr>
<td>NERF</td>
<td>Non-Eligibility Report Form</td>
</tr>
<tr>
<td>NHS R&amp;D</td>
<td>National Health Service Research &amp; Development</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>PIC</td>
<td>Participant Identification Centre</td>
</tr>
<tr>
<td>PIS</td>
<td>Participant Information Sheet</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomised Control Trial</td>
</tr>
<tr>
<td>REC</td>
<td>Research Ethics Committee</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious Adverse Event</td>
</tr>
<tr>
<td>SAP</td>
<td>Statistical Analysis Plan</td>
</tr>
<tr>
<td>SAR</td>
<td>Serious Adverse Reaction</td>
</tr>
<tr>
<td>SDV</td>
<td>Source Data Verification</td>
</tr>
<tr>
<td>SOP</td>
<td>Standard Operating Procedure</td>
</tr>
<tr>
<td>SS</td>
<td>Site Staff</td>
</tr>
<tr>
<td>SSI</td>
<td>Site Specific Information</td>
</tr>
<tr>
<td>SUSAR</td>
<td>Suspected Unexpected Serious Adverse Reaction</td>
</tr>
<tr>
<td>TMF</td>
<td>Trial Master File</td>
</tr>
<tr>
<td>TMG</td>
<td>Trial Management Group</td>
</tr>
<tr>
<td>TSC</td>
<td>Trial Steering Committee</td>
</tr>
</tbody>
</table>
### iii. TRIAL SUMMARY

<table>
<thead>
<tr>
<th>Trial Title</th>
<th>Evaluating the Home-based Intervention Strategy (HIS-UK) to reduce new Chlamydia infection among young men aged 16-25 years by promoting correct and consistent condom use. What is the cost effectiveness of two different delivery models (face-to-face and digital delivery)?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Internal ref. no. (or short title)</td>
<td>Evaluation of HIS-UK</td>
</tr>
<tr>
<td>Trial Design</td>
<td>Randomised controlled superiority trial with three-parallel groups (two intervention and one control arm, 1:1:1 allocation), with an internal pilot.</td>
</tr>
<tr>
<td>Trial Participants</td>
<td>Young men aged 16-25 years who are at risk of sexually transmitted infections.</td>
</tr>
<tr>
<td>Planned Sample Size</td>
<td>2231 - Including 135 in the pilot phases.</td>
</tr>
<tr>
<td>Treatment duration</td>
<td>Education and training consultation plus 2 weeks of self-practice sessions at home.</td>
</tr>
<tr>
<td>Follow up duration</td>
<td>12 months</td>
</tr>
<tr>
<td>Planned Trial Period</td>
<td>56 months</td>
</tr>
<tr>
<td><strong>Objectives</strong></td>
<td><strong>Outcome Measures</strong></td>
</tr>
<tr>
<td>Primary</td>
<td>To assess the effectiveness of HIS-UK to reduce new Chlamydia infection as compared to usual condom distribution care.</td>
</tr>
<tr>
<td>Secondary</td>
<td>To assess the effectiveness of HIS-UK to improve correct and consistent condom use as compared to usual condom distribution care.</td>
</tr>
</tbody>
</table>
iv. FUNDING AND SUPPORT IN KIND
The trial is funded by NIHR Public Health Research Programme.

v. ROLE OF TRIAL SPONSOR
The trial sponsor (University of Southampton) assumes overall responsibility for the initiation and management of the trial for the trial design, conduct, data analysis and interpretation, manuscript writing, and dissemination of results. The trial sponsor will ensure that there are robust arrangements for managing, monitoring, and financing the trial in accordance with the U.K. Policy Framework for Health and Social Care Research.

vi. ROLES AND RESPONSIBILITIES OF TRIAL MANAGEMENT COMMITTEES/GROUPS & INDIVIDUALS

 Trial Management Group (TMG)
The TMG will comprise the CI and all Co-Investigators (clinical and non-clinical) and members of the BSCTU and CRN. The TMG will be responsible for the day-to-day running and management of the trial. It will hold regular teleconferences and face-to-face meetings.

 Project Advisory Group (PAG)
The stakeholder and user representative PAG is chaired by the Director of the Centre for Sexual Health Research at the University of Southampton. Members (TBC) will include representatives of organisations with specific interest in the study (for example, Terence Higgins Trust, FPA, Brook, the British Association for Sexual Health and HIV, the Society of Sexual Health Advisors, the Sex Education Forum, Public Health England, and NICE), health promotion professionals, academics, policy makers and user representatives. This group will meet with the investigators quarterly to oversee the execution of the study and provide advice and assistance.

 Dissemination Working Group (DWG)
A sub-group of the PAG, along with an additional five user representatives, will form the DWG. Chaired by our PPI Co-investigator, the role of this group is to provide advice and recommendations on our dissemination and impact strategy.

 Trial Steering Committee (TSC)
The TSC has membership from the senior members of the TMG, representatives of the research network and independent members (researcher, statistician and clinician, PPI rep). The role of the TSC is to provide overall supervision for the trial conduct and advice through the independent Chair. The TSC will meet biannually.

 Data Monitoring and Ethics Committee (DMEC)
The DMEC has three independent members, with one having clinical trial expertise, one a researcher in the field, and one an expert trial statistician. The DMEC will meet at least annually (more, if needed). The trial statisticians will produce reports to the DMEC. The DMEC will consider data using the pre-agreed statistical analysis plans and will advise the TSC. The DMEC can recommend premature closure or reporting of the trial or discontinuation of recruitment to any research arm.

Details of all members can be found on the trial website www.his-uk.net

vii. KEY WORDS: Chlamydia, Condoms, Young Men, Public Health, Digital Health, Behaviour Change Intervention
viii. TRIAL FLOW CHART

[Flowchart description]

Evaluation of HIS-UK
1. BACKGROUND AND RATIONALE

Sexually transmitted infections (STIs) are a major public health concern in the UK. The Department of Health (DoH) has identified the need to reduce STI rates as a priority for decreasing sexual health inequalities and have recognised young male and female heterosexuals and men who have sex with men (MSM) as target ‘at-risk’ groups [1]. The health, social, and economic costs of STIs are huge and current estimates suggest that treatment costs the NHS £620 million per year [2]. Chlamydia (the most common diagnosis) and gonorrhoea are largely symptomless infections which, left untreated, can result in serious complications, including infertility.

Correct and consistent condom use is the most effective method to reduce STI transmission [3]. Public Health England have recently launched a campaign to protect young people from STIs by using condoms [4]. There is, however, substantial evidence that condoms are often not used properly. There are many reported barriers to condom use such as negative attitudes, decreased sensation and reduced sexual pleasure, fit-and-feel problems, application issues, and erection difficulties [5].

Behaviour change intervention programmes typically try to improve knowledge and skills to increase condom use, but seldom focus on addressing the reasons for condom non-use as important determinants. Issues with the fit-and-feel of condoms are commonly cited by men who report inconsistent or incorrect condom use [6,7] and these negative experiences are highly likely to be responsible for much of the variation in condom use self-efficacy and outcome expectancies known to be related to consistent use [8-10]. In a review of the evidence, we found that only five of 123 studies identified focused on improving condom fit-and-feel [11]. The intervention we propose to evaluate addresses the condom use barriers (including errors and problems) faced by young men by encouraging practice and experimentation. The intervention has already shown promise in feasibility and pilot studies [12-15].

The DoH recommends that evidence-based preventative interventions be used to reduce STI rates [16]. Yet, current national guidelines regarding behavioural interventions to prevent STIs are limited. A review of the evidence on safer sex advice recommended that brief behaviour change interventions targeting individuals and focusing upon skills acquisition, communication competences and motivation to adopt safer sexual behaviours should be provided as part of routine care of those at elevated risk of STIs [17]. In practice, there is scant information about whether such discussions occur and, if so, whether they are effective in reducing risk behaviour. Moreover, many communication and motivational interventions are very resource and cost-intensive. Funding for sexual health services has reduced dramatically, so novel ways of preventing STIs that reduce staff time and clinic attendance are being sought. Indeed, given the increasing use of the internet by young people to obtain health information, NHS England has identified the need to make fuller use of digital technologies [18]. There is therefore a need to develop and evaluate brief behavioural interventions that can be easily implemented without the need for high levels of staff resources.

Recent guidelines from the National Institute for Health and Care Excellence (NICE) include the need to teach young people to use condoms effectively and safely (using education, information and demonstrations) before providing them, and to provide a range of condoms and lubricants [19]. NICE also recommended that future research should explore what behaviour change techniques are most effective for supporting consistent and correct condom use following their distribution [19,20].

Systematic reviews of the efficacy of behaviour change interventions for the promotion of consistent condom use have produced mixed results [21-23]. Poor quality trials and a failure to identify the active components (or behaviour change techniques) of interventions have reduced the ability of studies to inform future development. Yet there is emerging evidence, mainly from US studies, that brief behavioural interventions designed with identifiable and evidence-based components can reduce STI acquisition [9,17,24].

The intervention we want to evaluate meets the above policy and practice recommendations. HIS-UK aims to improve men’s condom use skills, self-efficacy, and enjoyment by providing information and guidance on condom experimentation, practice and usage (using a range of different condoms and
lubricants). During its development, we coded the behaviour change techniques and potentially active components of existing promising condom promotion interventions to enable the development of a brief behavioural intervention that is evidence based and theoretically driven [15].

HIS-UK has been adapted from an intervention previously piloted in the US and Canada (The Kinsey Institute Homework Intervention Strategy: KI-HIS). Pilot studies of KI-HIS showed significant improvements in condom use experiences, self-efficacy for condom use, and condom fit and feel, as well as a reduction in breakage and erection problems among heterosexual young men [12] and MSM [13]. Ongoing studies in the US are testing a female and a couple-based version. Preliminary results from the feasibility and pilot testing in the UK has shown a significant increase in reported use of lubricants during condom use, an increase in condom use at last intercourse, an improvement in condom use attitudes, in the fit-and-feel of condoms used, and enhanced sexual enjoyment during condom use [15,25].

HIS-UK has been designed with two delivery models: delivery by a trained health promotion professional (proHIS) or as a digital intervention using an interactive website (eHIS). ProHIS has been designed as an extension of usual condom demonstration and distribution care model currently practiced by health promotion professionals and offered to young people in condom distribution settings. The purpose of digital delivery (eHIS) is to facilitate improved access to a preventative STI intervention without the need of specialist provider contact. Furthermore, individuals and groups with the greatest need for sexual health services are also those least likely to be able to access them. Digital interventions (DIs) such as eHIS remove accessibility barriers that contribute to health inequalities and enable participation at a time and location convenient to users, provide anonymity and can reduce fear of stigmatisation. DIs also have the advantage of providing consistency and standardisation in delivery and implementation costs that are typically low compared to other delivery methods.

The development work already undertaken to adapt KI-HIS to HIS-UK, and the two delivery formats of proHIS and eHIS, ensures that the proposed interventions are acceptable to young men and suitable to roll out [15,25]. What we now need to know is whether proHIS and eHIS are effective in promoting behaviour change and reducing STIs, and what is the cost effectiveness of the two delivery models as compared to usual condom distribution care.

2 ASSESSMENT AND MANAGEMENT OF RISK

This trial is categorised as Type A = No higher than the risk of usual medical care.

Condoms are the most effective method to reduce STI transmission. Non-use of condoms during penetrative vaginal or anal intercourse can lead to increased risk of infection.

HIS-UK aims to improve men’s condom use skills, self-efficacy, and enjoyment by providing information and guidance on condom experimentation, practice and usage. Participants in this trial are provided with information and training regarding correct condom identification and use and then issued with a range of different condoms and lubricants to try out and test.

The primary philosophy behind HIS-UK is to enhance autonomous motivation for behaviour change by focusing on solitary practice of condoms, similar to the behavioural therapy approach used to treat sexual problems which incorporates home-based exercises. In common with the sex therapy approach, the exercises are designed to increase focus on pleasurable sensations whilst using condoms, thereby challenging beliefs that condoms “spoil” sex.

---

1 Condoms are not ‘medical treatment’ and therefore do not need to be provided by a ‘qualified medical practitioner’. The term ‘Health Promotion Professionals’ represents all trained workers, including non-medical practitioners such as youth workers, working in settings where condom provision can be offered.
The testing of different condoms and lubricants for fit, feel and sensation is not considered to carry any significant risks to the young men who participate in this trial and is comparable to the risks and benefits of the use of condoms and lubricants provided during standard condom distribution care. The benefits to the young men who participate include the chance to try out a range of condom and lubricant types and find the ‘best’ brand for them.

Young men with a known allergy to latex are excluded from the trial. There is a small but potential risk, however, that a young man registers for the trial and is not aware that they have latex allergy.

The proportion of the UK population with an allergy to latex is not known. Best estimates suggest that in the general population up to five percent are believed to have an allergy although many do not show significant or any symptoms so are probably unaware.

Symptoms of latex allergy typically occur immediately; however, some people have a delayed reaction that is more likely to be an itchy rash. Following screening participants who report that they are “unsure” if they have a latex allergy will be highlighted to the site staff who will then further question the participant to determine level of risk. Men who report previous symptoms will be excluded from the trial, those deemed to be at low risk with no previous allergen history will be allowed to continue but instructed to cease use of all condom products and to contact the site immediately if they experience any adverse reactions.

Condoms and lubricants containing nonoxynol-9 spermicide (N-9) will not be used in the trial as this has been shown to cause damage to human tissue, leading to inflammation and ulceration, which is dose-related.

3 OBJECTIVES AND OUTCOME MEASURES/ENDPOINTS

3.1 Research Question

1) Does the UK Home-based Intervention Strategy (HIS-UK) delivered face-to-face by health professionals (proHIS) and digitally delivered by an interactive website (eHIS) reduce Chlamydia test positivity among young men aged 16-25 years by enhancing condom use experiences and improving correct and consistent condom use as compared to usual condom distribution care?

2) What is the cost effectiveness of the two different delivery models of HIS-UK (face-to-face (proHIS) and digital delivery (eHIS)) as compared to usual condom distribution care?

3.2 Aim

To assess the effectiveness and cost effectiveness of HIS-UK delivered by two intervention delivery models (face-to-face (proHIS) and digital (eHIS)) to reduce test positivity of Chlamydia among young men aged 16-25 years by enhancing condom use experiences and improving correct and consistent condom use, as compared to usual condom distribution care.

3.3 Objectives

1) To assess the effectiveness of HIS-UK among young men aged 16-25 years by comparing face-to-face delivery (proHIS), digital delivery (eHIS) and usual condom distribution care:

   • Chlamydia test positivity at 6 and 12 months
   • Episodes of condomless anal and/or vaginal sexual intercourse at months 1-12
   • Reported condom use errors and problems at months 1-12
   • Enhanced condom use experiences (‘fit & feel’, sensitivity, pleasure and self-efficacy) at months 1-12
   • Positive condom use attitudes at months 1-12.

2) To conduct a mixed method process evaluation to explore the ways in which HIS-UK delivered by proHIS and eHIS may work, possible mediators and mechanisms of change, and participants’ experiences of engaging with the intervention and trial.
3) To estimate the costs associated with HIS-UK delivered by proHIS and eHIS and their cost effectiveness as compared to usual condom distribution care.

3.4 Outcome Measures

3.4.1 Primary Health Outcome

1. Chlamydia test positivity rate

Chlamydia will be measured at baseline (T0), 6 months (T6) and 12 months (T12) through bio-marker testing and treatment, and at T1-T12 through self-reporting. The primary health endpoint will be test positivity rate at 6 months. To examine longevity of intervention effect, test positivity will be assessed up until twelve-months post randomisation.

3.4.2 Secondary Process Indicators

These will be assessed using the following validated online questionnaires obtained at baseline (T0), and at monthly intervals to 12 months (T1-T12) and supported by qualitative data collected via interviews with participants recruited during wave 1.

2. Condom Barriers Scale [30]
3. Condom Use Errors and Problems Survey [31]
5. Multidimensional Condom Attitude Scale [33]
6. Sexual Behaviour and Contraceptive Use Survey (sexual partner history, relationship status/type, frequency of intercourse, use of contraception/condoms)

Further outcome data will be collected to inform an economic analysis, as detailed in the table below and in section 9.5.2.

3.5 Table of Endpoints/Outcomes

<table>
<thead>
<tr>
<th>Objectives</th>
<th>Outcome Measures</th>
<th>Time points</th>
</tr>
</thead>
<tbody>
<tr>
<td>To assess the effectiveness of HIS-UK to reduce new Chlamydia infection as</td>
<td>Chlamydia test positivity rate.</td>
<td>Baseline and then 6&amp;12 months post intervention.</td>
</tr>
<tr>
<td>compared to usual condom distribution care.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>To assess the effectiveness of HIS-UK to improve correct and consistent</td>
<td>Condom Barriers Scale.</td>
<td>Baseline and then monthly questionnaires to 12</td>
</tr>
<tr>
<td>condom use as compared to usual condom distribution care.</td>
<td>Condom Use Errors and Problems Survey.</td>
<td>months post intervention.</td>
</tr>
<tr>
<td></td>
<td>Condom Use Self-Efficacy Scale.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Multidimensional Condom Attitude Scale.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sexual Behaviour and Contraceptive Use.</td>
<td></td>
</tr>
<tr>
<td>Assess the cost effectiveness of the two different delivery models of HIS-</td>
<td>EQ5D / SF-12 Costs and resource use.</td>
<td>Baseline and then 6&amp;12 months post intervention.</td>
</tr>
<tr>
<td>UK compared to usual care.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
4 TRIAL DESIGN

To compare the effectiveness of HIS-UK delivered face-to-face by health professionals (proHIS) and HIS-UK digitally delivered by an interactive website (eHIS) to usual condom distribution care we will carry out a randomised, controlled, superiority trial with three-parallel groups (two intervention and one control arm, 1:1:1 allocation), with an internal pilot. We will use a repeated measures trial design with baseline measurement (T0) and follow-up monthly online questionnaires to 12 months (T1-12) post intervention and three STI screening points (T0,T6,T12) for Chlamydia. We will collect health economic data to compare the resource use and cost-effectiveness of delivering HIS-UK by the two delivery models to that of usual condom distribution care.

5 TRIAL SETTING

The trial is multi-centred and will be run in up to ten NHS Trust sites.

Participants will be recruited at selected integrated sexual health (SH) and Genitourinary Medicine (GUM) services and University associated Health Centres/GP practices. Community and educational youth advisory, information and counselling (YAIC) services, Health Centres, GP practices and community SH/GUM outreach facilities will be used to further advertise the study and signpost interested young men to the recruitment sites.

The HIS-UK intervention comprises three key elements:

- Focused condom and lubricant education and training.
- Solitary condom and lubricant experimentation and practice.
- Online ratings of condoms and lubricants.

The first element is designed to be delivered by either a trained health professional or self-delivered in a home environment using the internet. The second two elements are designed to be self-delivered by the participants and undertaken in a home environment.

Participants will be required to return to the recruitment site at 6 months and 12 months post intervention to undertake Chlamydia screening unless a Chlamydia screening postal-kit option is able to be offered from the service and is chosen by the participant.

6 PARTICIPANT ELIGIBILITY CRITERIA

6.1 Inclusion criteria

- Men and people with attributes of a biological male (i.e. a penis).
- Aged 16-25 years.
- Self-reported residency in England.
- At risk of STIs through reporting of condom use errors (i.e. breakage/slippage) or condomless penile-vaginal or penile-anal intercourse with casual/non-regular or new sexual partners during the previous three months.
- Willingness to commit to the trial duration.
- Capable of giving informed consent.

6.2 Exclusion criteria

- People without attributes of a biological male (i.e. a penis)
- A recognised latex allergy.
- No access to the internet.
- Limited written and/or spoken English proficiency sufficient to prevent the following of trial instructions.
7 TRIAL PROCEDURES AND TREATMENTS

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advertising</td>
<td>Integrated sexual health and genitourinary medicine (GUM) services</td>
</tr>
<tr>
<td></td>
<td>Sexual health/GUM community outreach facilities</td>
</tr>
<tr>
<td></td>
<td>Community and educational youth advisory, information and counselling (YAIC) services</td>
</tr>
<tr>
<td></td>
<td>Social Media</td>
</tr>
<tr>
<td></td>
<td>GP Practices/Health Centres</td>
</tr>
<tr>
<td>Recruitment, consent and registration</td>
<td>Sexual health/GUM services</td>
</tr>
<tr>
<td></td>
<td>University associated Health Centres/GP practices</td>
</tr>
<tr>
<td>Baseline data – Questionnaire</td>
<td>Sexual health/GUM services</td>
</tr>
<tr>
<td></td>
<td>University associated Health Centres/GP practices</td>
</tr>
<tr>
<td>Baseline data – Screening</td>
<td>Sexual health/GUM services</td>
</tr>
<tr>
<td></td>
<td>University associated Health Centres/GP practices</td>
</tr>
<tr>
<td>Intervention delivery</td>
<td>Control – Sexual health/GUM services &amp; University associated Health Centres/GP practices</td>
</tr>
<tr>
<td></td>
<td>proHIS- Sexual health/GUM services &amp; University associated Health Centres/GP practices</td>
</tr>
<tr>
<td></td>
<td>eHIS- at home</td>
</tr>
<tr>
<td>Intervention delivery analytics</td>
<td>Control – at home</td>
</tr>
<tr>
<td></td>
<td>proHIS – at home</td>
</tr>
<tr>
<td>Intervention activities (kit testing)</td>
<td>At home</td>
</tr>
<tr>
<td>Intervention activities (rating forms)</td>
<td>At home</td>
</tr>
<tr>
<td>Follow-up assessments – Questionnaires</td>
<td>At home</td>
</tr>
<tr>
<td>Follow-up assessments – Screening</td>
<td>At home (postal kits)</td>
</tr>
<tr>
<td></td>
<td>Sexual health/GUM services</td>
</tr>
<tr>
<td></td>
<td>University associated Health Centres/GP practices</td>
</tr>
</tbody>
</table>

7.1 Recruitment

The trial will employ recruitment of participants through targeted advertisements and opportunistic direct approach.
7.1.1 Participant identification

Participants will self-identify to the trial through publicity (e.g. posters, fliers/leaflets, online and digital adverts, trial website, and targeted social media adverts) and/or via direct approach in recruitment sites by trained site staff (SS).

Furthermore, targeted advertisements, posters and fliers placed in health, community and educational settings will be used to advertise the trial and signpost interested young men to appropriate sites to register. Young men who are signposted to recruitment sites from external trial adverts will identify themselves to reception staff on arrival and introduced to the recruiting staff for eligibility screening.

7.1.2 Screening

No laboratory testing or diagnostic screening will be required to meet any noted inclusion or exclusion criteria.

7.1.3 Payment

To compensate for the “burden” imposed by the research all participants will receive electronic voucher payments totalling £50 (£10 after active participation for three months, £15 after participation for six months, and £25 after twelve months participation).

7.2 Eligibility Checking and Consent

The Principal Investigator (PI) retains overall responsibility for the conduct of research at their site; this includes receiving of informed consent from eligible participants at their site. Authorised, trained and competent staff (SS) will be identified and delegated responsibility by the site PIs to receive informed consent.

Informed consent will be obtained prior to the participant undergoing any procedures that are specifically for the purposes of the trial and are outside standard routine care. Consent will be obtained prior to trial registration, randomisation or the collection of any identifiable participant data collection.

Potential participants will be given sufficient time to read any information provided before deciding whether or not they are interested in finding out more. For those who are interested SS will conduct, with verbal consent, an initial eligibility check using a computer assisted questionnaire administered by Lifeguide to ensure relevance of recruitment progression. A count of men who do not meet the eligibility check and for what reason/s will be collated. SS will be required to record the reason for non-eligibility on the site NERF (a tally of the known reported reasons for non-progression).

NOTE: Lifeguide is an interactive web-based intervention software platform and secure validated data management system designed to collect participant information and deliver digital interventions (DI) to support health behaviour change. Tablet computers supporting the Lifeguide software will be provided to the sites by the trial sponsors. Tablets with 4G connectivity will be provided in sites with poor WIFI.

If eligibility is met, SS will provide full written details (patient information sheet), verbally explain the trial and answer questions. Informed online consent will be taken on the Lifeguide platform using the tablet computer on site. A count of eligible men who express an interest in the trial who then do not provide consent will be collected within Lifeguide. Reasons for non-participation will be recorded where provided.

It is a requirement for this trial that all participants are sufficiently proficient in spoken and written English (the eHIS digital intervention is only available as an English language website). It is also the responsibility of the SS to assess the capability of potential participants to provide informed consent to understand the purpose and nature of the research, what is involved, its benefits, risks and burdens and the alternatives to taking part. They are also required to determine that potential participants have been given sufficient time to make an effective and free decision to participate (a person is assumed to have the mental capacity to make a decision unless it is shown to be absent). During the
discussions that occur during the recruitment, information sharing and consent processes, the SS will determine whether participants are able to understand the nature of the trial and what is associated with their participation, are capable of providing consent and therefore fulfil the trial eligibility criteria.

Following consent, participants register themselves to the trial on the Lifeguide platform. SS will check the participant is also registered as a patient at the recruitment setting. If not, a patient registration will be made. Patient ID numbers will be transferred to the CRF for the purposes of Chlamydia screening data transfer between the trial sites and the research team.

The right of a participant to refuse participation without giving reasons will be respected and all participants will be free to withdraw at any time from the trial without giving reasons and without prejudicing his further treatment; he will also be provided with a contact point where he may obtain further information about the trial (see the participant information sheet for more details).

The site PI and SS will take responsibility for ensuring that all vulnerable participants are protected and participate voluntarily in an environment free from coercion or undue influence. In situations where a participant is able to consent initially for the trial but later becomes incapacitated the original consent endures the loss of capacity.

The research team will provide appropriate training for the site PI and SS to undertake all the required activities and process including the trial recruitment and consent processes.

7.2.1 Translation

The eHIS digital intervention is only available as an English language website, and as such trial materials will only be provided in English and no translation service will be offered.

7.3 The Randomisation Scheme

Following trial registration each participant will be prompted to complete a baseline self-completion computer assisted questionnaire (T0). On submission of the T0 data participants will be instructed to pass the tablet computer back to the SS. The SS will then be prompted to authorise the T0 submission (on-screen button) which will activate the randomisation algorithm built into Lifeguide. The algorithm will use randomly permuted blocks of varying length to preserve concealment and maintain balance within each recruitment setting site, with stratification by ethnicity and sexual orientation to randomly allocate the participate to a trial arm.

Participants will be allocated to one of the three trial arms at a ratio of 1:1:1.

SS will be informed of the outcome of the randomisation process by an on-screen notification message on the tablet computer. The research team will be able to review all randomisation details via the Lifeguide database.

Sites are required to

- ‘Flag’ active trial participants along with their participant ID on relevant patient records.
- Keep secure all CRF containing participant IDs and associated patient ID numbers to facilitate data transfer between clinical sites and the research team.

7.4 Blinding

The individual trial participants will not be blinded to the trial. Furthermore, trained SS are required to deliver all three intervention arms (proHIS, eHIS and usual care) and as such are not blinded to the trial.

To avoid bias and potential contamination between trial arms each SS member will be required to demonstrate competency by simulating usual care and proHIS intervention delivery with another SS member or a trial researcher (recorded for independent competency checking) following training.

Within each recruitment site, in a 7% random selection of cases (20% during wave 1 recruitment) the interaction with the SS member will be audio-taped and assessed for intervention fidelity by a blinded
independent assessor from the research team, with any discrepancies discussed with a second blinded assessor. Participants will provide consent for this recording to take place.

In all cases where proHIS and usual condom distribution care is delivered, SS will be asked to complete a checklist detailing all training and education activities undertaken (providing valuable analytics of intervention delivery and dosage). Similar questions will also be asked of all participants allocated to the usual care control arm and the proHIS intervention arm by way of a short survey administered by Lifeguide after participant registration. Assessors (research team members) of this data will be blinded.

Members of the research team undertaking the primary endpoint data analysis will also be blinded.

7.5 Baseline data

7.5.1 Questionnaire (T0)

Following participant registration each participant will be prompted to complete a baseline self-completion computer assisted (T0) questionnaire (administered via Lifeguide). The baseline questionnaire will collect basic demographics (age, ethnicity, postcode, sexual orientation, education, employment and housing), quality adjusted life years (QALYs) and health service resource use. Data will also be collected on a series of behavioural, condom use experience, attitudinal, intentions and self-efficacy outcome measures, along with details of any partnered sexual activity and condom use that had occurred in the previous four-week period. The collection of postcoded data enables each participant to be assigned to an Index of Multiple Deprivation Score based on the geographical locality in which they live.

7.5.2 Screening

Each participant is required to provide samples for Chlamydia detection. Participants who report sex with other men (highlighted to the SS on the tablet computer following submission of T0 data) will be triple tested, as per usual clinical practice (urine sample, and anal and oral swab); all other participants will be requested to provide a single urine test for analysis.

Collection of intimate swabs (anal and oral swabs for men who have sex with men) may cause some embarrassment. Where possible men who have sex with men will be triple tested for Chlamydia; however, if the participant refuses for any reason, a single urine test will be offered rather than removing the participant from the study (see flowchart). Participants who refuse an anal swab but consent to provide an oral swab and urine test will be classed as agreeing to a triple test for the purpose of the study.

At baseline SS will facilitate the collection of samples (via clinic screening, or postal kits if clinic screening is not possible) and the sites will be responsible for the laboratory analysis of the sample.

If the participant has been tested for Chlamydia within 4 weeks of the baseline visit as part of standard of care, the results from this test may be used for the study and the participant will not be required to provide any samples for Chlamydia detection at the baseline visit. SS will assess and inform the participant when this will be applicable.

Sites will be required to share the screening outcome data with the research team via the Lifeguide platform or the University of Southampton’s password secured Encrypted Electronic Safesend Service.

All positive Chlamydia tests will be treated as per standard care.

Flowchart: Summary of the triple testing refusal process
MSM participant asked by study site staff to be triple tested for Chlamydia.

Study site staff emphasise the benefits of being triple tested for Chlamydia.

Do they consent to be triple tested?

- No
- Yes

Do they consent to be triple tested?

- No
- Yes

Offer single Chlamydia test (Urine test)

Do they consent to be single tested?

- Yes
- No

Continued participant involvement, however only self-reported data obtained

Participant provides urine sample

Participant triple tested
7.6 **Intervention Delivery and Activities**

### 7.6.1 Control Arm

Usual care is the comparator control condition. Participants randomly allocated to the control arm receive:

1. Standard condom distribution care consultation offered in the recruitment setting.
2. Details about the *Lifeguide* platform (to complete follow-up T1-T12 questionnaires).

### 7.6.2 HIS-UK Intervention Arms

The HIS-UK intervention comprises three key elements:

a) Focused condom and lubricant education and training.

b) Solitary condom and lubricant experimentation and practice.

c) Online ratings of condoms and lubricants

This trial compares two delivery models for the HIS-UK focused education and training (element (a)), namely face-to-face delivery by a trained health promotion professional (proHIS) and digital delivery by way of an online website (eHIS).

### 7.6.3. Education and Training

#### 7.6.3.1 Face-to-Face Delivery: proHIS

Participants randomised to the proHIS intervention arm will receive a face-to-face consultation with the trained SS during which each participant will receive:

1. A verbal consultation introducing HIS-UK, including the need for and advantages of condom testing and self-practice.
2. A comprehensive condom application demonstration using a penile demonstrator to teach correct condom use competency. To meet the competency requirement, each participant will be asked to repeat back the demonstration to the SS member until no errors are made.
3. Information about using condoms for pleasure, and how to find the best condom for fit and feel.
4. Information about lubricants, their benefits, and how to use them.
5. An overview of the condom information and self-practice instruction guide containing details of the home-based exercises and how to rate the condoms and lubricants tested.
6. A condom kit containing 24 condoms (minimum of eight different types, shapes and sizes) and 12 sachets of lubricant (three different types).
7. Details about the *Lifeguide* platform with access to the condom/lubricant rating forms and T1-T12 questionnaires.

#### 7.6.3.2 Digital Delivery: eHIS

Participants randomised to the eHIS intervention arm will receive the following from the SS:

1. A condom kit containing 24 condoms (minimum of eight different types, shapes and sizes) and 12 sachets of lubricant (three different types).
2. Details about the *Lifeguide* platform with full access rights to the eHIS website (authorised within *Lifeguide* at randomisation), the condom/lubricant rating forms and T1-T12 questionnaires.

Using interactive digital media (information, videos and serious gaming) the eHIS website will provide:

1. An introduction to HIS-UK, including information about condoms, and the need for and advantages of condom testing and self-practice.
2. Teaching on correct condom use (how to apply and remove a condom).
3. Information about using condoms for pleasure, and how to find the best condom for fit and feel.
iv) Information about lubricants, their benefits, and how to use them.

v) Advice on condom self-practice and details of condom use exercises to try out at home.

vi) Details on how to test and rate the condoms and lubricants provided in the condom kit.

### 7.6.4 Solitary Experimentation and Practice

Following education and training all participants in the two intervention arms (proHIS and eHIS) commence a two-week condom/lubricant experimentation and self-practice period using the contents of the condom kits and following the guided home-based exercises. The aim is for participants to practice applying, using (masturbating with) and removing each of the condoms provided in the condom kit in “low pressure” situations (i.e., not in the presence of a sexual partner) and to try out and experiment with the different lubricants.

As young men try out each condom and lubricant, they are asked to focus on pleasurable sensations in order to build positive associations between condom use and sexual enjoyment.

### 7.6.5 Condom and Lubricant Rating

After experimentation with each condom/lubricant, participants are requested to complete an online rating and feedback form using the *Lifeguide* platform. The purpose of the rating form is to enable participants to identify the condoms that ‘fit & feel’ the best, and the lubricant of choice. *Lifeguide* agents facilitate automated texts and e-mails to prompt intervention arm participants to complete the required ratings over the 2-week self-practice period (days 3, 7 and 12). Protocol compliance is defined as a minimum of three submitted rating forms and full compliance as the submission of eight.

At the end of the 2-week rating period, proHIS and eHIS intervention participants who adhere to minimum protocol compliance are offered 12 condoms of their choice and six sachets of their preferred lubricant via the post.

### 7.6.6 Intervention Delivery Analytics

Participants randomised to proHIS and the control arm will be contacted via *Lifeguide* notification (e-mail/text) 24 hours after registration to complete a brief checklist survey of the training and education activities that were undertaken during the consultation.

The web pages of eHIS are delivered by *Lifeguide* and managed by a series of intelligent “agents” (interaction, information, instruction, and evaluation). The purpose of the agents is to manage and monitor the learning of individuals by observing and recording e-learning behaviour (i.e., pages visited, instructional videos watched) and triggering automated messages and prompts to guide and assist effective learning (to visit further information pages, undertake tasks, watch video clips) and ensure exposure to all learning elements by participants.

### 7.7 Long Term Follow-Up Assessments

#### 7.7.1 Monthly Questionnaires

All participants (proHIS, eHIS and control) will receive automated texts/emails every month (via *Lifeguide* agents) for 12 months, prompting them to complete an online assessment questionnaire (T1-T12) as per baseline (T0).

Participants are required to complete each questionnaire within 21 days of first notification. Automated reminder messages (days 3, 7, and 12) will be sent (text and/or email) until completion. Final contact will be made by the research team (personalised telephone call and/or e-mail) between days 15-21 to determine the status of trial participation. Following the telephone discussion, if no further questionnaires are completed the participant will have deemed to have withdrawn from the trial.

Following submission of each monthly questionnaire, proHIS and eHIS intervention arm participants who have been sexually active in the previous month will be prompted to order further supplies of condoms and lubricants of their choice should they wish (12 condoms and six lubricants). The
research team will be notified of all condom orders and will be responsible for mailing out supplies.

### 7.7.2 Chlamydia Screening

At 6 months and 12 months post intervention, each participant is required to provide samples for Chlamydia detection.

To reduce research ‘burden’ on trial participants and to minimise attrition, only participants who have reported sexual activity in the previous six months (T1-T6) will be prompted to undertake follow-up screening. Furthermore, if a participant reports Chlamydia screening within 4 weeks of the 6 months and 12 months follow-up time points, the results from this screening may be used for the study and the participant will not be required to provide further samples for detection. Participants will be notified of the need to be screened via an on-screen message following submission of the T6 and T12 questionnaire data using the *Lifeguide* software.

Participants who have reported penetrative anal sex with other men during the previous 6 months (@T6 reporting sex with other men between T1 and T6; @T12 reporting sex with other men between T7 and T12) will be offered a triple test (urine sample, and anal and/or oral swab). All other participants who report penetrative anal or vaginal sex with only women will be requested to provide a single urine test for analysis.

Where possible, men who report sex with men will be triple tested for Chlamydia; however, if the participant refuses for any reason, a single urine test will be offered as an alternative. If a single urine test is refused, the participant will be allowed to continue with the study and their self-reported STI screening data will be used. Participants who are offered triple testing but refuse an anal swab and consent to provide an oral swab and urine test will be classed as agreeing to a triple test for the purpose of the study.

To reduce research ‘burden’ on trial sites, the protocol for follow-up screening of Chlamydia will vary depending on the ability of each site to provide postal screening (see below).

Following the submission of the T6/T12 questionnaire data a *Lifeguide* on-screen message will offer participants who require follow-up screening the option to receive a postal Chlamydia screening kit or to present for screening at the service setting in which they registered. Those who opt for postal screening are asked to confirm their personal contact details for the purposes of kit delivery and notification of results.

#### A. Sites providing postal kits to participants

Sites will be notified by the research team of those participants who opt to obtain a postal kit. Relevant participant ID numbers and contact details will be shared with the sites via secure e-mail, along with the type of kit required (single or triple). Sites are required to consult the participant/patient ID database (CRF), mail out screening kits and flag the mail out on the associated patient record and CRF.

Sites will be responsible for collection and laboratory analysis of the sample and are required to share the screening outcome data with the research team via the *Lifeguide* platform or University of Southampton’s password secured Encrypted Electronic Safesend Service. Appropriate training will be provided.

If after three weeks a participant has not returned samples for screening *Lifeguide* will automatically send them a reminder message (text and/or email) to return the postal kit or choose instead to present for screening at the service setting in which they registered.

A final contact will be made by the research team (personalised telephone call and/or e-mail) three weeks later if a screening has still not occurred. If a sample is still not provided the screening outcome data at T6/T12 will be marked as missing.

All positive results will be treated as per usual NHS care.
B. Sites unable to provide postal kits to participants

Some sites might not be able to provide the required postal kits or there may be internal restrictions for sites to send participants who opt to obtain a postal kit during the follow up period, and the following protocol may be substituted.

Sites are required to consult the participant/patient ID database (CRF) and inform the research team if they are unable to provide a postal kit to the relevant participant and reason why (i.e. participant has moved outside the site’s catchment area). The research team will arrange for screening kits to be mailed out and will be responsible for the collection and laboratory analysis of the samples.

If after three weeks a participant has not returned samples for screening participants will automatically receive a reminder message (text and/or email) to return the postal kit or choose instead to present for screening at the service setting in which they registered.

Final contact will be made by the research team (personalised telephone call and/or e-mail) three weeks later if a screening has still not occurred. If a sample is still not provided the screening outcome data at T6/T12 will be marked as missing.

Outcome data will be entered on to the Lifeguide platform by the Research team and Participant ID numbers and screening results will be shared with the sites via secure e-mail.

All positive results will be treated as per usual NHS care.

C. Participants choosing to present in person

Participants who opt to return to the recruitment setting are given three weeks in which to present for screening. They are sent three reminders by way of auto generated text messages and/or e-mails sent via Lifeguide.

Sites will be notified by the research team of those participants who opt to present in person. Relevant Participant ID numbers will be shared with the sites via secure e-mail, along with the type of kit required (single or triple).

If after three weeks a participant has not presented for follow-up screening, Lifeguide will automatically send them a message (text and/or email) repeating the option to receive a postal Chlamydia screening kit or to present for screening at the service setting in which they registered.

A final contact will be made by the research team (personalised telephone call and/or e-mail) three weeks later if a screening has still not occurred. If a sample is still not provided the screening outcome data at T6/T12 will be marked as missing.

All positive results will be treated as per usual NHS care.

7.8 Qualitative Assessments

Consistent with MRC guidance and a person-based approach to the delivery of interventions [49], mixed-methods will be used to examine how the intervention was implemented, possible mechanisms of impact, and contextual factors that may have influenced implementation of the intervention.

Qualitative in-depth interviews will be undertaken with all SS in the three recruitment sites following wave 1 participant recruitment. The purpose of these interviews is to explore acceptability of the research design and intervention delivery, including how easy it was to recruit to the trial, willingness of participants to be randomised, ease of acquiring STI screening and data transfer, and issues of intervention fidelity.
To measure process and potential contamination between trial arms qualitative assessments of the delivery of proHIS and the control arm will be undertaken. Within each recruitment site, in a 7% random selection of participant cases (20% during wave 1 recruitment) the consultation interaction with the SS will be audio-taped and transcribed and assessed for intervention fidelity. Randomisation to this recording will occur within Lifeguide. SS will be informed of the outcome of the randomisation process by an on-screen notification message on the tablet computer; research team members will be notified via automated e-mail. Participants will provide consent for this recording to take place.

The research team will then contact SS to organise collection of the digital recorder and recording. Digital recorders containing recordings will be kept secure by SS until a collection has been organised.

At T6 and T12 follow-up, all wave 1 participants will be asked (via Lifeguide) if they would be willing to be contacted by the research team and be interviewed about the trial (either face-to-face or by telephone). From those who agree, 20 participants at each time point will be purposively sampled based on baseline characteristics to ensure a range of participant experiences are represented. The purpose of these interviews is to explore 1) trial acceptability, 2) issues of contamination and protocol adherence, and 3) how and why the intervention may/may not be beneficial. We expect that 20 interviews at each time point will be sufficient to reach theoretical saturation; however, if necessary, additional interviews will be undertaken with participants from subsequent waves. All participants will be required to give consent for the interviews to be digitally recorded, transcribed and analysed.

7.9 Withdrawal

Participants have the right to withdraw from the trial at any time without giving a reason. Sites have the right to withdraw participants from the trial if they judge this to be in the participant’s best interests following participant behaviour and/or information shared during the consultation and intervention delivery.

Participants will have deemed to have withdrawn from the trial if they fail to submit three successive monthly questionnaires (T1-T12).

Should a participant decide to withdraw from the trial, all efforts will be made to report the reason for withdrawal as thoroughly as possible (participants will be asked for their consent to be interviewed, or to communicate the reasons for their decision in writing/e-mail). Participants will also be asked if they consent for the reason for their decision to withdraw to be recorded within Lifeguide.

Consent will be sought from participants choosing to withdraw to retain data collected up to the point of withdrawal. If this is not given, no personal data will be retained.

Participants will be replaced if they withdraw prior to randomisation.

Data and samples collected up to the point of withdrawal will only be used after withdrawal if the participant has consented to this.

If a participant withdraws from the trial, all efforts will be made to report the reason for withdrawal. Participants will be asked for their consent to be interviewed by phone, or to communicate the reason for their decision in writing.

7.10 Trial progression

The first wave of recruitment will be run as an internal pilot to assess trial acceptability, intervention fidelity, and the feasibility of randomisation and Chlamydia screening for trial continuation.

Assessment of progression will be made based on a pilot cohort of 135 young men recruited within 3 months, followed up for a period of six months; the findings from in-depth process interviews conducted with all SS and a sub-sample of up to 20 young men; and the assessment of intervention fidelity recordings.

During this period the following questions will be answered:

- Can we recruit eligible young men at a reasonable rate and to the numbers anticipated?
- Are young men willing to be randomised within the trial?
Evaluation of HIS-UK

- Is Chlamydia screening at T0 and T6 sufficiently acceptable and feasible to implement?
- Do young men remain in the trial in sufficient numbers at six month follow-up?
- Are the intervention and trial design sufficiently acceptable?
- Are SS able to deliver the intervention with reasonable fidelity?

If the trial is stopped prematurely. Participants will be notified by text/e-mail and participant payments honoured.

7.11 Storage and Analysis of Clinical Samples

Samples obtained: Urine / anal and oral swabs.

The collection, analysis, storage and destruction of all biological samples will be as per usual care.

It is the responsibility of the trial site to ensure that samples are appropriately labelled in accordance with the trial procedures to comply with GDPR (2018). Biological samples collected from participants as part of this trial will be transported, stored, accessed and processed in accordance with national legislation relating to the use and storage of human tissue for research purposes and such activities shall at least meet the requirements as set out in the 2004 Human Tissue Act and the 2006 Human Tissue (Scotland) Act.

7.12 Supply and Distribution of HIS-UK Intervention Condoms and Lubricants

Ordering

Usual care condoms and lubricants supplied in the HIS-UK kits will be purchased and provided by the sites through the standard supply chain. The research team will organise collection and transportation of usual care condoms to the University of Southampton for inclusion in the HIS-UK condom kits and the mail-out supplies at T1-T12.

Non-usual care condoms supplied in the HIS-UK condom kits will be sourced and supplied by the research team (discounted commercial supply). Reimbursement for the cost of these will be sought from sites through the offset against site research costs unless costs can be covered by other means.

Distribution

The research team will make-up and distribute the HIS-UK kits to the trial sites. The research team will also be responsible for the postal distribution of condoms and lubricants ordered by HIS-UK trial participants at T1 to T12.

Each site will be provided with 100 HIS-UK kits at site activation. When the remaining kit numbers fall below 30, sites will be sent further supplies by the research team.

At the end of the trial

Any remaining HIS-UK kits may be utilised by the sites at the end of the trial and are not required to be returned to the research team.

7.13 Assessment of Compliance

Participants randomised to the proHIS arm are required to demonstrate condom competency to the SS during the intervention education and training consultation.

SS provide a comprehensive condom application demonstration using a penile demonstrator to teach correct condom use competency. To meet the competency requirement, each participant must repeat back the demonstration to the SS until no errors are made. Competency is recorded within Lifeguide.

Compliance to the HIS-UK home-based exercises will be monitored and assessed by the research team through the number of condom/lubricant rating forms submitted by eHIS and proHIS participants. Protocol compliance is defined as a minimum of three submitted rating forms and full compliance as the submission of eight.

To examine compliance of the eHIS intervention participants' access to and usage of the eHIS intervention will be recorded within Lifeguide. All compliance data will be collated from Lifeguide.
8 SAFETY

8.1 Definitions

International Conference for Harmonisation/Good Clinical Practice (ICH/GCP) requires that both investigators and Sponsor to follow specific procedures when notifying and reporting adverse events/reactions in research studies. These procedures are described in this section of the protocol.

For this Non-CTIMP trial only reports of Serious Adverse Events (SAEs) that are:

- Related to the trial (i.e. they resulted from administration of any of the research procedures)
- Unexpected (i.e. not listed in the protocol as an expected occurrence)

will be submitted to the REC that approved the trial using the Non-CTIMP safety report to REC form. These will be sent within 15 days of the Chief investigator (CI) becoming aware of the event.

Table 1: Definitions applicable in HIS-UK trial

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse Event (AE)</td>
<td>Any untoward medical occurrence in a patient treated on a trial protocol, which does not necessarily have a causal relationship with a trial intervention. An AE can therefore be any unfavourable and unintended sign, symptom or disease temporally associated with the use of a trial intervention, whether or not related to that trial treatment.</td>
</tr>
</tbody>
</table>
| Serious Related Event or Unexpected Serious Related Event. | Any related event or unexpected event that meets the definition below that can be attributed to the trial/intervention/procedure, that:  
- Results in death  
- Is life-threatening*  
- Requires inpatient hospitalisation** or prolongation of existing hospitalisation  
- Results in persistent or significant disability or incapacity (based on clinician’s judgement)  
Will be reported. |

Life-threatening (*), in the definition of ‘serious’, refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.

Hospitalisation (**) is defined as an inpatient admission, regardless of length of stay, even if the hospitalisation is a precautionary measure for continued observation. Hospitalisations for a pre-existing condition (excluding psychosis) including elective procedures that have not worsened do not constitute an SAE.
8.2 Causality and Expectedness

Table 2. Definitions of Causality for Serious Related Events

<table>
<thead>
<tr>
<th>Relationship</th>
<th>Description</th>
<th>Event Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrelated</td>
<td>There is no evidence of any causal relationship.</td>
<td>Not reported</td>
</tr>
<tr>
<td>Unlikely</td>
<td>There is little evidence to suggest there is a causal relationship (e.g. the event did not occur within a reasonable time after administration of the trial intervention). There is another reasonable explanation for the event (e.g. the patient’s clinical condition, other concomitant treatment).</td>
<td>Not reported</td>
</tr>
</tbody>
</table>
### Evaluation of HIS-UK

<table>
<thead>
<tr>
<th>Possible</th>
<th>Serious Related</th>
</tr>
</thead>
<tbody>
<tr>
<td>There is some evidence to suggest a causal relationship (e.g. because the event occurs within a reasonable time after the trial intervention, and there is some possible link to the trial). However, the influence of other factors may have contributed to the event (e.g. the patient’s clinical condition, other concomitant treatments).</td>
<td>Using the reporting form report within 24 hours of being made aware to <a href="mailto:BSCTUsafety@bsms.ac.uk">BSCTUsafety@bsms.ac.uk</a> and to the site PI</td>
</tr>
<tr>
<td>Definitely</td>
<td>Serious Related</td>
</tr>
<tr>
<td>There is clear evidence to suggest a causal relationship and other possible contributing factors can be ruled out.</td>
<td>Using the reporting form report within 24 hours of being made aware to <a href="mailto:BSCTUsafety@bsms.ac.uk">BSCTUsafety@bsms.ac.uk</a> and to the site PI</td>
</tr>
<tr>
<td>Unexpected</td>
<td>Unexpected Serious Related Event</td>
</tr>
<tr>
<td>It is not consistent with the available information for this trial intervention.</td>
<td>Using the reporting form report within 24 hours of being made aware to <a href="mailto:BSCTUsafety@bsms.ac.uk">BSCTUsafety@bsms.ac.uk</a> and to the site PI</td>
</tr>
</tbody>
</table>

For example, related events may be as follows:

I. Embarrassment, discomfort, anxiety or distress caused by contents of the educational training, booklet or website;

II. Embarrassment, discomfort, anxiety or distress caused by undertaking the HIS-UK home-based exercises;

III. Embarrassment, discomfort, anxiety or distress caused by answering questionnaires or taking part in the interviews;

IV. Disappointment at being allocated to the control arm;

V. Distress caused by concern about data security and confidentiality in the trial (routine text and e-mail messages);

VI. Anxiety or distress caused by concern about risk to sexually transmitted infection and risk taking sexual behaviours;

VII. Others as deemed by the site.

**Expectedness**

The expectedness of the SAE will be assessed by the local delegated investigator (named PI) and the CI and must be reported to the BSCTU within 24 hours of the site being made aware (bsctu@bsms.ac.uk).
8.3 Reporting and Responsibilities

Notification Procedure for Serious Related and Unexpected Serious Related Events.

1. The initial form must be completed by a member of the SS team who is on the delegation of responsibilities log.

2. Send the initial form with as much information as possible by email to BSCTUsafety@bsms.ac.uk and the PI as soon as site becomes aware of it. The PI reassess the causality and assess the expectedness. The initial report shall be followed by detailed, follow up reports as appropriate.

3. Follow-up: Patients must be followed-up until clinical recovery is complete, or until the event has resolved. Follow-up should continue after completion of protocol treatment if necessary. Follow-up information must be reported on the follow-up/final report. In the absence of the PI, the form should be completed and signed by another trained member of the site staff team who is named on the delegation log (as designated by local PI). The PI should subsequently check the form, make changes as appropriate, sign and then send to the Brighton & Sussex CTU as soon as possible. The patient must be identified by a participant ID number. The patient’s name must not be used on any correspondence. This final report is then graded on the basis of expectedness judged by the PI and CI.

4. The BSCTU will notify the research ethics committee of as per the conditions of the favourable opinion and according to CTUSOP018 within 15 calendar days of the BSCTU first being notified of the event.

It is the responsibility of the BSCTU in collaboration with the CI for:

1. Central data collection and verification of all reported events according to the trial protocol onto a database.
2. Reporting safety information to the independent oversight committees identified for the trial (Data Monitoring Committee (DMC) and / or Trial Steering Committee (TSC)) according to the Trial Monitoring Plan.
3. Notifying Investigators of events that occur within the trial.
4. Preparing standard tables and other relevant information for timely submission to the MHRA and REC.

Trial Steering Committee (TSC):
In accordance with the Terms of Reference for the TSC, periodically reviewing safety data and liaising with the DMC regarding safety issues.

Data Monitoring Committee (DMC):
In accordance with the Terms of Reference for the DMC, periodically reviewing overall safety data to determine patterns and trends of events, or to identify safety issues, which would not be apparent on an individual case basis.

8.4 Urgent Safety Measures

The Sponsor, PI or CI may take appropriate safety measures in order to protect research participants against any immediate hazard to their health or safety, without prior authorisation from a regulatory body. The REC that approved the trial will be notified immediately and in any event within three days, in the form of a substantial amendment that such measures have been taken and the reasons why.

8.5 Notification of Deaths

Only deaths that are assessed to be caused by the intervention will be reported to the sponsor. This report will be immediate.
8.6 Safeguarding of Participants

Safeguarding means protecting a person’s right to live in safety, free from abuse and neglect. All NHS staff have a responsibility to safeguard people in their care, but extra care must be taken to protect those who are least able to protect themselves. Children and young people, and vulnerable adults, can be at particular risk of abuse or neglect. A child is a person aged under 18 years. Responsibilities for safeguarding are enshrined in legislation.

Within the NHS clinic setting:

Any allegation received during the study registration process that suggests the participant to be at risk of significant harm (physical harm, emotion and psychological harm, sexual harm and exploitation, neglect) will be dealt with under the NHS safeguarding policy.

Contacts with the research team:

If a participant divulges any worries or concerns in relation to the study during follow-up, the researcher will signpost the young person to a source of advice and support. In the event of a participant divulging information that is considered to pose an immediate risk, such as the intention to harm themselves or allegation of abuse, then any confidentiality agreements will be overridden and the participant will be informed that their information will be passed through the University of Southampton’s Safeguarding system so they are supported. Allegations will be discussed with the Principal Investigator, in order to make a risk assessment as soon as possible, and to agree actions and possible contact with external agencies e.g. Police, Social Services. Nominated Safeguarding Officers/Leads and Clinical Leads may also be involved at this stage. The young person cannot refuse for this referral to occur.

9 STATISTICS AND DATA ANALYSIS

9.1 Sample Size Calculation

For the purposes of sample size estimation the primary health outcome is the test positivity rate of Chlamydia at six months post randomisation.

The effectiveness of HIS-UK delivered by proHIS and eHIS will be analysed with an overall Type I error rate of 5% (2.5% per comparison), comparing test positivity among each of the intervention arms with the control arm (usual care). Data published by the National Chlamydia Screening Programme suggest a test positivity rate of 11% among young men aged 15-24 years in England tested in specialist sexual health services. [28] The trial is powered to detect a reduction in Chlamydia test positivity rates among young men in our intervention arms from 11% to 6% (a 45% reduction) at six months post randomisation.

Previous piloting suggests that the intervention is likely to be equally effective across all subgroups (deprivation, ethnicity, sexual orientation, age) [15,25].

In order to have 85% power to obtain the projected difference in the analyses requires 476 participants in each of the arms (G*Power 3.1.9.2). To minimise risk to the trial and to reflect 36% attrition at follow-up (observed during our HIS-UK feasibility testing) [15], a total of 2231 participants will be randomised over a period of 30 months during three recruitment waves.

9.2 Planned Recruitment Rate

Participants will be randomised during three recruitment waves:

- Wave 1 (months 1-3) 135 young men;
- Wave 2 (months 4-15) 540 young men;
- Wave 3 (months 16-30) 1556 young men.

We have based our recruitment time calculations on an estimated site recruitment rate of 15 young men randomised per calendar month.
Waves 1 and 2 of recruitment will take place within three NHS Trust regions.

Additional sites (up to 10 in total) will recruit during Wave 3; these will be selected in consultation with partnering NHS Trusts determined following a CRN-facilitated expression of interest call via the trial support service.

9.3 Statistical Analysis Plan

9.3.1 Data Analysis

Analysis and presentation of data will be in accordance with the revised CONSORT 2010 statement. The statistical analysis will be performed on available cases following intention-to-treat principles (ITT) with due emphasis placed on confidence intervals for the between-arm comparisons. Baseline demographic (age, ethnicity, deprivation, sexual orientation, etc.) and self-reported outcome measure data (secondary process indicators) will be assessed for comparability between the arms using descriptive analyses.

The primary analysis will be undertaken using generalised linear modelling to compare the effectiveness of the active HIS-UK intervention delivered by proHIS and by eHIS to reduce the test positivity rate of Chlamydia at 6 months versus treatment as usual (control group). The analysis will be replicated for test positivity at twelve months to examine the longevity of any intervention effect.

The extent of missing data will be reported and baseline factors will be compared from completers and non-completers to assess the extent of any bias that may result. As our analysis is based on ITT principles, withdrawals and protocol violators will be analysed in their arms as randomised. Depending on the extent of any missing data and the potential of any bias, a further analysis may be undertaken on those participants who complete, as compared to the ITT results. Following multiple imputation sensitivity analysis with variable assumptions will be undertaken to investigate the potential effects of missing data.

Analyses will be extended to include the investigation of possible intervention moderators and mediators, the exploration of process measures (for example, number of condom tests completed), and which young men benefit from proHIS and eHIS the most (age, sexual orientation, ethnicity, social deprivation).

Similar comparative analyses using the secondary process indicators (those through which the primary outcome is likely to be realised) collected at T0-T12 will be undertaken using generalised linear mixed modelling to allow for the analysis of repeated measurements over time and comparison between the trial arms.

9.4 Interim Analysis and Criteria for the Premature Termination of the Trial

The first wave of recruitment will be run as an internal pilot to assess trial acceptability, intervention fidelity, and the feasibility of randomisation and Chlamydia screening for trial continuation. Assessment of progression will be made based on a pilot cohort of 135 young men recruited within 3 months, followed up for a period of six months; the findings from in-depth process interviews conducted with all SS and a sub-sample of up to 20 young men; and the assessment of intervention fidelity recordings.

During this period we aim to answer the following questions:

- Can sites recruit eligible young men at a reasonable rate and to the numbers anticipated?
- Are young men willing to be randomised within the trial?
- Is Chlamydia screening at T0 and T6 sufficiently acceptable and feasible to implement?
- Do young men remain in the trial in sufficient numbers at six-month follow-up?
- Are the intervention and trial design sufficiently acceptable?
- Are SS able to deliver the intervention with reasonable fidelity?

9.4.1 Progression criteria

   a) Min 75% target recruitment number at three months
   b) Min 85% of eligible participants willing to be randomised
c) Min 90% uptake of STI screening at T0 and 64% of those at T6

d) Maximum 36% attrition at 6 months

e) Intervention fidelity rated highly

f) Min of two additional recruitment sites enrolled to the trial at three months

Based on the outcomes of the criteria, the following scenarios are possible: No outcomes met (stop, main trial not realistic); some outcomes met and others amenable to improvement, such as enhanced recruitment strategies or alternative STI screening strategy (continue, main trial realistic with modifications); all criteria met (continue, main trial realistic with current design).

9.5 Economic Evaluation

The economic analysis will analyse the costs and outcomes associated with the three arms of the trial. This will involve evaluating the costs and benefits of the two delivery models for the HIS-UK intervention (pro-HIS and e-HIS), as compared with usual care. If pro-HIS and/or eHIS are effective in improving competency for consistent and correct condom use and reducing the incidence of STIs, there are likely to be important cost implications for the healthcare sector, for the wider public sector, and for society as a whole. The primary base case analysis will therefore adopt a public sector perspective, as far as this is possible, with healthcare and patient perspectives undertaken as secondary analyses.

9.5.1 Data Collection

Resource use data will be collected prospectively to estimate the costs associated with each of the trial arms (for the two delivery models for the intervention and for usual care). This will include: (1) the cost of the HIS-UK intervention delivery, for face-to-face (pro-HIS) and digital (eHIS) models, and the cost of usual care. For example: (1) The costs of the condom kits, consultation costs, costs associated with digital delivery, and other resource use; (2) costs experienced after receiving the HIS-UK intervention (delivered by proHIS and eHIS) or usual care; for example, condom costs, GP/sexual health service visits, other public resource use; (3) costs associated with the treatment of any STIs and other conditions; (4) personal costs experienced by young people; for example, travel costs, internet use, out-of-pocket expenses. Information on unit costs or prices will be sourced to attach to each resource use item, to enable an overall cost per participant to be calculated. e.g.,[35]

Resource use data will be captured via a variety of mechanisms. Firstly, within the trial, the resource use and costs associated with delivering proHIS and eHIS and any follow-up care (for example, in relation to treatment of STIs in clinic) will be captured via trial reporting mechanisms. The main focus will be on the differences in resource use between the two different delivery models, and in relation to usual care. Wider NHS and public sector resource use will be captured via a questionnaire for young people; this will include the use of medication, Health Centre/GP visits, sexual health centre visits and other public sector resource use. We will also capture any patient costs associated with receiving the intervention (via the two models of delivery) and usual care.

Alongside the clinical outcomes collected in the trial and in line with recommendations from the National Institute of Health and Care Excellence (NICE), data will also be captured that will allow quality-adjusted life years (QALYs) to be used as outcome measures in the cost-effectiveness analysis. [36] It is recommended that QALYs are calculated so that cost-effectiveness can be compared across disease areas. This will require changes in health-related quality of life (HRQL) to be captured for all trial arms. While the EQ-5D-5L [37] is the questionnaire recommended by NICE to measure HRQL, NICE also recognises that this measure may not be suitable within economic evaluations of public health interventions. [38] This is particularly the case with sexual health interventions, which have an important psychosocial aspect. [39] For this trial, HRQL will therefore be collected using the SF-12 instrument, which has previously been successfully used in a related context [40] and the EQ5D-5L instrument. These questionnaires will be administered to compare changes in health-related quality of life for the three arms, at T0, T6 and T12 time periods.
9.5.2 Economic Analysis

In order to assess the costs and benefits of HIS-UK (delivered via proHIS and eHIS) compared with usual care, both a within trial analysis and a model-based economic analysis will be undertaken.

9.5.2.1 Within Trial Analysis

The within trial analysis will use the data collected within the trial, and so estimates of costs and benefits will relate to the initial period of 6 months and extended to 12 months, based on the primary outcome associated with the trial. The data used for this analysis will primarily be the trial-specific resource use data and costs. The main economic analysis will assess cost-effectiveness based on incremental cost per QALY gained at 6 months, with a secondary analysis of cost per case of Chlamydia avoided at 6 months, reflecting the primary outcome of the trial; this analysis will then be repeated to measure cost-effectiveness over a 12-month period. Initially, the base case analysis will be framed in terms of a cost-consequence analysis for the three trial arms, and data will be reported in a disaggregated manner on the incremental cost and important consequences assessed in the trial.

9.5.2.2 Model-based Analysis

If the trial shows that proHIS and/or eHIS are effective in reducing Chlamydia incidence and other condom use health behaviour outcomes, compared with usual condom distribution care, it will be necessary to assess the cost-effectiveness of the intervention delivery models in the longer term. Therefore, if deemed necessary, based on the results of the trial, a decision-analytic model will be used to extrapolate costs and outcomes beyond the end of the trial and synthesise data on costs and outcomes from a range of sources. [41] The evidence used in the model will be drawn from the trial and a comprehensive review of the literature. The literature review will include evidence on condom use and failure, prevalence of Chlamydia and other STIs, transmission rates and long term outcomes. If data availability permits (based on an assessment of the results of the RCT and the literature review), a public sector perspective will be adopted, as well as an NHS perspective, in line with recommendations [36, 42]. The review of the literature will evaluate existing economic evaluations and models, to inform the design and parameters of the model developed as part of the trial. There are a range of published economic models in this area, some focussing specifically on interventions to improve condom use, and these publications will be used to inform model construction e.g., [39, 43]. The final model will compare the incremental benefits gained and costs for the proHIS and eHIS interventions compared with usual care, over the lifetime of the patients where possible.

9.5.2.3 Presentation of Results and Sensitivity Analyses

The economic evaluation will be conducted and reported in accordance with relevant guidelines. [44, 45] Results will be presented using cost-effectiveness acceptability curves (CEACs) to show the uncertainty surrounding the cost-effectiveness of the proHIS and eHIS interventions, for a range of thresholds for cost-effectiveness. [46] We shall use both deterministic and probabilistic sensitivity analyses (PSA) to explore the inherent uncertainty around the estimates employed in the evaluation. [41] The choice of distributions for the PSA will be based upon current best practice in modelling. [47] For the longer-term analyses, discounting will be undertaken to reflect recommendations by NICE and the Treasury.
10 DATA MANAGEMENT

10.1 Data Collection Tools and Source Document Identification

The investigator/institutions will keep records of all participants (excluding patient ID numbers). Trial sites will hold all participant case report forms (CRF – which contain sufficient information to link to patient records) unless instructed otherwise by the sponsor.

All participant source data will be collated within Lifeguide and stored on the Lifeguide server located within the University of Southampton iSolutions secure research data storage service. Lifeguide is an interactive web-based intervention software platform and secure validated data management system designed to collect participant information and deliver digital interventions (DI) to support health behaviour change. [26]

For the purposes of analysis the following software packages will be used:

- IBM SPSS Statistics
- Stata
- Excel
- MLwiN

10.1.1 Source Data

ICH E6 section 1.51, defines source data as "All information in original records and certified copies of original records or clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data are contained in source documents (original records or certified copies)."

- Eligibility screening data
- Consent data
- Baseline questionnaire data (T0): standardised and non-standardised tools
- Consultation digital recordings
- Screening outcome data
- Condom/lubricant rating forms
- Follow-up questionnaire data (T1-T12)
- Follow-up screening outcome data
- Audio recordings and transcripts from interviews

10.1.2 Source Documents

ICH E6 1.52, defines source documents as "Original documents, data and records (e.g., hospital records, clinical and office charts, laboratory notes, memoranda, participants' diaries of evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x-rays, participant files, and records kept at the pharmacy, at the laboratories, and at medico-technical departments involved in the clinical trial)."

Case report forms (CRF) and Non-eligibility response forms (NERF) are considered source documents. If instructed source documents are to be transmitted to the sponsor. NERF documents which do not contain participant data are to be transmitted via registered post. CRF documents will be transferred by courier. It is necessary for the trial sites to retain copies of all CRF and NERF to ensure that the PI has an independent account from the sponsor as to what has occurred during the trial at their site.
10.2 Data Handling and Record Keeping

All trial procedures will comply with the relevant General Data Protection Regulation (GDPR) and in accordance with the University of Southampton’s Research Data Policy and that of the collaborating institutions.

The research team will ensure that all research data and records are:
- Accurate, complete, authentic and reliable;
- Identifiable, retrievable, and available when needed;
- Secure and safe;
- Kept in a manner that is compliant with our legal obligations (and the requirements of the funding body); and
- Able to be made available to others in line with appropriate ethical, data sharing and open access principles.

All data generated as part of the trial (electronic and hard copy) will be securely stored in line with procedures approved by the Faculty of Environmental and Life Sciences Ethics Committee at the University of Southampton.

All electronic data (including media files from digital recordings) will immediately be transferred and stored in the University of Southampton iSolutions secure research data storage service. The data stored within these facilities is regularly backed up and, a copy of the back-up in Southampton is regularly off-sited to a secure location for disaster recovery purposes. Only authorised users can access data stored within these facilities and it is managed under the governance of the University of Southampton’s Research Data Management Policy. Anonymised transcripts (anonymised at the point of transcription) and any personalised data collected will also be stored on the University’s managed storage in separate password protected folders. Transfer of pseudonymised electronic data between the research institutions will be via the University of Southampton’s password secured Electronic Safesend Service or courier. Transfer of participant data between the sites and the University of Southampton will be via the University of Southampton’s password secured Electronic Safesend Service.

Hard-copy data will be securely stored in lockable filing cabinets. All personalised data will be independently stored (in separate filing cabinets) from hard-copy notes and transcripts.

Personal respondent information will not be released to, or viewed by, anyone other than that of the research team working on the project.

Data collected during the trial will be used only for research purposes, and results will be presented in a publicly available final report. Results of the trial will also be submitted for publication in scientific journals, presented at scientific conferences, and disseminated to government departments, non-governmental organisations, health professionals, educators, academics and the general public as part of educational activities. No identifiable data (such as names or addresses) will be used in any publication or dissemination activity.

10.3 Access to Data

Direct access will be granted to authorised representatives from the Sponsor/host institution/CTU and the regulatory authorities to permit trial-related monitoring, audits and inspections- in line with participant consent.

10.4 Archiving, data documentation and preservation

Standard metadata procedures (e.g. Datacite) will be followed to ensure others are able to find, access and ultimately reuse data generated as part of this trial, with DOIs being issued for the dataset and data subsets as per the University of Southampton’s DOI policy. Metadata records for the data (and published outputs) will also be maintained on the University of Southampton Institutional Research Repository. In accordance with the University's Data policy, the data will be archived in an appropriate
repository (UK Data Service, eprints and Dspace, for example) for a minimum of ten years after publication or last access, whichever is longer, to ensure long term access and safeguarding of the data and resulting outputs.

Future users of the data will be bound by data sharing agreements. Where suitable, a licence (currently Creative Commons) can be applied to data deposited in the repository.

10.5 Data Destruction

To enable the secure disposal of locally held electronically data, the Sponsor retains an external company that specialises in destroying magnetic and solid state media and will provide a "Certificate of Assurance".

Print based materials will be destroyed carefully by shredding. Additionally, Southampton University Estates and Facilities provide a service for the specific removal of shredded confidential waste, defined as "material containing sensitive personal or business sensitive data which requires destruction to ensure that the contents remain private in order to comply with GDPR".

11 Monitoring, Audit & Inspection

A Trial Monitoring Plan will be developed and agreed by the Trial Management Group (TMG), TSC and CI based on the trial risk assessment that may include on-site monitoring. This will be dependent on a documented risk assessment of the trial.

The processes reviewed will relate to participant enrolment, consent, eligibility, allocation to trial groups, adherence to trial interventions and policies to protect participants. Monitoring will be done by exploring the trial dataset, scrutiny of consultation digital recordings, telephone discussions with site PIs and, if necessary, by performing site visits.

Monitoring will be performed across all recruitment sites and will be undertaken by staff at Brighton and Sussex CTU in collaboration with the research team at University of Southampton.

12 Ethical and Regulatory Considerations

12.1 Research Ethics Committee (REC) Review & Reports

Before the start of the trial, approval will be sought from the University of Southampton Research Integrity and Governance (RIG) Office for the trial protocol, informed online consent forms and other relevant documents as required. HRA approval will then be sought.

Substantial amendments that require review by REC will not be implemented until the REC and the University of Southampton RIG Office grants a favourable opinion for the trial.

All correspondence with the HRA will be retained in the Trial Master File (TMF) Management system.

An annual progress report (APR) will be submitted to the REC within 30 days of the anniversary date on which the favourable opinion was given, and annually until the trial is declared ended.

It is the Chief Investigator’s responsibility to produce the annual reports as required.

The Chief Investigator will notify the REC of the end of the trial.

If the trial is prematurely ended, the Chief Investigator will notify the REC, including the reasons for the premature termination.

Within one year after the end of the trial, the Chief Investigator will submit a final report with the results, including any publications/abstracts, to the REC.

12.2 Peer review

This protocol has been reviewed and agreed by NIHR Public Health Research Programme (funder).
12.3 Public and Patient Involvement

PPI will be actively involved in all of the following stages of the research:

- Design of the research
- Management of the research
- Contributing to developing ethics information and consent forms, trial advertisements
- Developing participant information resources
- Contributing to the reporting of the research
- Providing feedback on the final eHIS webpages
- Conducting interviews with participants
- Dissemination of project findings

The trial has a PPI representative (RN) as a named co-applicant. RN will sit on the Trial Steering Committee, Trial Management Group, Project Advisory Group and chair the Dissemination Working Group. In addition to RN, there will be additional PPI representatives recruited to sit on the Project Advisory Group and the Dissemination Working Group.

All PPI representatives will be recruited by RN from across the research sites with support from the other Co-Is. The role of the PPI representatives who sit on the Dissemination Working Group is to be actively involved in the development of the impact and dissemination strategy and all associated activities.

All PPI Advisory Group members will be offered a range of training activities, including learning sessions, quality materials and guidance, conference attendance opportunities (with opportunities to present if they wish), peer shared learning experiences and skills development courses (e.g., presentation skills). Project mentoring along with practical and emotional support will be provided through peer support mechanisms and team meetings.

The opportunity to train PPI representatives to conduct elements of the research (follow up in-depth interviews) will be explored. The involvement of young men in all of the above stages will ensure that the trial reflects their concerns/interests. All PPI activities and training have been costed appropriately using INVOLVE methodology.

12.4 Regulatory Compliance

Before any site can enrol participants into the trial, the Chief Investigator/Principal Investigator or designee will ensure that appropriate approvals from participating organisations are in place. Specific arrangements on how to gain approval from participating organisations are in place and comply with the relevant guidance.

For any amendment to the trial, the Chief Investigator or designee, in agreement with the sponsor, will submit information to the appropriate body in order for them to issue approval for the amendment. The Chief Investigator or designee will work with sites (R&D departments at NHS sites as well as the trial delivery team) so they can put the necessary arrangements in place to implement the amendment to confirm their support for the trial as amended.

12.5 Protocol Compliance

Prospective, planned deviations or waivers to the protocol are not allowed and must not be used e.g., it is not acceptable to enrol a participant if they do not meet the eligibility criteria or restrictions specified in the trial protocol.

Accidental protocol deviations can however happen at any time. They must be adequately documented on the relevant forms and reported to the BSCTU and Chief Investigator immediately.

Deviations from the protocol which are found to frequently recur are not acceptable, will require immediate action and could potentially be classified as a serious breach.
12.6 Notification of Serious Breaches to GCP and/or the Protocol

A “serious breach” is a breach that is likely to effect to a significant degree:
(a) the safety or physical or mental integrity of the participants of the trial; or
(b) the scientific value of the trial

The sponsor will be notified immediately of any case where the above definition applies during the trial conduct phase.

12.7 Financial and other Competing Interests for the Chief Investigator, PIs at each Site and Committee Members for the Overall Trial Management

We will identify and disclose in our final report any competing interests that might influence trial design, conduct, or reporting.

This will include:

- Ownership interests that may be related to products, services, or interventions considered for use in the trial or that may be significantly affected by the trial.
- Commercial ties requiring disclosure include, but are not restricted to, any pharmaceutical, behaviour modification, and/or technology company.
- Any non-commercial potential conflicts e.g. professional collaborations that may impact on academic promotion.

12.8 Indemnity

Appropriate arrangements have been put in place for insurance and/or indemnity to meet the potential legal liability of the sponsor for harm to participants arising from the management and/or design of the research.

Appropriate arrangements (NHS indemnity scheme) will be put in place for insurance and/ or indemnity to meet the potential legal liability of sites arising from harm to participants in the conduct of the research.

Appropriate arrangements have been put in place for insurance and/or indemnity to meet the potential legal liability of the sponsor arising in relations to the supply of tablet computers to sites.

12.9 Amendments

If the sponsor wishes to make a substantial amendment to the REC application or the supporting documents, the sponsor must submit a valid notice of amendment to the REC for consideration. The REC/HRA will provide a response regarding the amendment within 35 days of receipt of the notice. It is the sponsor’s responsibility to decide whether an amendment is substantial or non-substantial for the purposes of submission to the REC/HRA.

All amendments must be approved by the University of Southampton RIG Office. Amendments also need to be notified to the national coordinating function of the UK country where the lead NHS R&D office is based and communicated to the participating organisations (R&D office and local research team) departments of participating sites to assess whether the amendment affects the NHS capacity and capability for that site. Note that some amendments that may be considered to be non-substantial for the purposes of REC still need to be notified to the HRA/NHS R&D (e.g. a change to the funding arrangements).

All amendments will be communicated to relevant stakeholders through the necessary communication channels.

Amendments history will be tracked by way of a version control table to identify the most recent protocol version.
12.10 Post-Trial Care
At the end of the trial all participants will be granted access to the eHIS website providing information and education regarding the effective and correct use of condoms and lubricants.

12.11 Access to the Final Trial Dataset
Only the CI and all Co-Investigators will have access to the full trial dataset. The dataset shared with the Co-Investigators will be pseudo-anonymised.

13 DISSEMINATION POLICY

13.1 Dissemination Policy
It is a funder requirement that all project outputs must be notified to the funder at least 28 days before publication or presentation. An output is any item arising from NIHR-funded research that enters the public domain. Outputs can be written, audio/visual, electronic or verbally presented. The NIHR takes a broad definition of what constitutes an output and must be acknowledged as the funder of the research in both oral and written outputs. All published material must contain an acknowledgement of funding, and when mentioning research findings or opinions, an appropriate disclaimer.

On completion of the trial, the data will be analysed and tabulated and a Final Trial Report prepared. The full trial report will be made available on the project website, relevant institutional websites that of the funder, along with an executive lay summary. Participants will be informed of this.

The Consort Guidelines and checklist will be reviewed prior to generating any publications for the trial to ensure they meet the standards required for submission to high quality peer reviewed journals. The CI has final approval of all outputs.

Authorship will be based on the following four criteria:

- Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
- Drafting the work or revising it critically for important intellectual content; AND
- Final approval of the version to be published; AND
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

In addition to being accountable for the parts of the work he or she has done, an author should be able to identify which co-authors are responsible for specific other parts of the work. In addition, authors should have confidence in the integrity of the contributions of their co-authors.

All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged.

As per the Sponsor Open Access Policy the following research outputs will be deposited and made publically available in the University of Southampton's institutional repository:

- The bibliographic metadata of all forms of published output, so there is a comprehensive record of research activity;
- The final, refereed, corrected, accepted manuscripts of all peer-reviewed journal articles and peer-reviewed conference articles at the point of acceptance for publication;
- Research data identified as significant under the University's Research Data Management Policy, including data underpinning publications;
- Outputs which the University issues with an ISSN, ISBN or DOI.
14 REFERENCES


## VERSION HISTORY

<table>
<thead>
<tr>
<th>Protocol version number</th>
<th>Date</th>
<th>Summary of changes/ Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>Aug 2019</td>
<td>N/A – Initial submission to REC</td>
</tr>
</tbody>
</table>
| 2.0                     | 23 Oct 2019| Response to REC･
- Typographical corrections, administrative and formatting changes
- Clarifications made in section 7.7.2 and 10.1 on data transfer
- New section 8.6 added – Safeguarding of participants |
| 3.0                     | 02 Dec 2019| Non-substantial amendment･
- Section 7.6.3 updated to a minimum of eight different types of condoms will be used in the study |
| 4.0                     | 03 Apr 2020| Substantial amendment･
- Section 6.1 Inclusion criteria updated to include participants experiencing condom errors in the study
- Section 7.5.2 and 7.7.2 Clarification on triple testing for chlamydia added
- Section 7.5.2 and 7.7.2 Standard of care chlamydia tests result performed within 4 weeks of the time point may be used at baseline, 6 month and 12 month follow up, if deemed appropriate to do so by site staff.
- Flowchart – summary of triple testing refusal processed moved from section 7.7.2 to 7.5.2
- Section 7.7.2 – Clarification on the postal kits process added and section re-ordered for simplification and clarity.
- Section 7.7.2 updated to reflect that all participants will be given the option of a postal kit. Sites that do not or unable to provide a postal service will be substituted for provision supplied by the research team.
- Section 7.8 - Clarification on the transfer of digital recordings added
- Typographical corrections, administrative and formatting changes throughout the protocol.
- Section 15 – Protocol version history added |